LG 30435 is a new bronchodilator agent with multiple sites of action

European Journal of Pharmacology
A SubissiA R Renzetti

Abstract

LG 30435, a new quaternary derivative of the H1-histamine antagonist mequitazine, was evaluated against bronchospasm induced by different agonists. This compound inhibited equipotently methacholine- and histamine-induced contractions of isolated guinea-pig trachea. When administered to guinea-pig by the i.v. and/or the aerosol route, LG 30435 inhibited dose dependently the bronchospasm induced by acetylcholine and histamine and to a lesser degree that induced by 5-hydroxytryptamine and LTD4. When compared to that of mequitazine, its potency was higher in each case, up to 500-fold when tested in vitro against methacholine. LG 30435 also counteracted antigen-induced bronchospasm both in passively sensitized guinea-pigs and in actively sensitized rats. This compound had a rapid onset of action and an adequate duration after aerosol administration. It was poorly absorbed both by the oral and the aerosol routes and it did not appear to penetrate the blood-brain barrier. These results show that LG 30435 is a new aerosol bronchodilator agent, which, due to its multiple pharmacodynamic actions and to its suitable pharmacokinetics, is potentially useful in the therapy of obstructive airways disease.

References

Nov 1, 1979·The Journal of Pharmacy and Pharmacology·J Emmerson, D Mackay
Jan 1, 1971·International Archives of Allergy and Applied Immunology·G E Davies, T P Johnston
May 21, 1982·European Journal of Pharmacology·A J LewisM E Rosenthale
Nov 22, 1984·The New England Journal of Medicine·M Kneussl, F Kummer
Jun 1, 1984·European Journal of Pharmacology·J ChangA J Lewis
Aug 16, 1984·The New England Journal of Medicine·J A Nadel
Jan 1, 1982·Pharmacology & Therapeutics·N M Eiser
Jun 1, 1955·British Journal of Pharmacology and Chemotherapy·D F HAWKINS

❮ Previous
Next ❯

Citations

Jul 17, 1990·European Journal of Pharmacology·A R RenzettiM Criscuoli
Dec 1, 1988·Prostaglandins·A SubissiM Criscuoli
May 1, 1994·The Journal of Pharmacy and Pharmacology·G D'AgostinoA Subissi
Apr 1, 1988·The Journal of Pharmacy and Pharmacology·A Subissi, M Del Monte

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Anaphylaxis

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.